ReviewPharmaceuticals (Basel, Switzerland)2021
Advances in Antifungal Drug Development: An Up-To-Date Mini Review.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Computational Discovery of Novel CYP51 Inhibitors for Antifungal Therapy Against Aspergillus fumigatus.Probiotics and antimicrobial proteins · 2026Article
- Quaternary Ammonium-Functionalized Chitosan as a Next-Generation Antifungal Platform: Chemistry, Mechanisms, and Therapeutic Applications.Marine drugs · 2026Review
- From Chemistry to Clinic: Amorphous Solid-State Modification Strategies for Oral Azole Antifungals.ACS omega · 2026Review
- In Vivo Evaluation of a Nanoemulsion-Delivered Chromium(III)-Triazole Complex Against Fluconazole-ResistantJournal of fungi (Basel, Switzerland) · 2026Article
- Bioactive Constituents ofDrug design, development and therapy · 2026Review
- Article
- Myco- and microbiological profiling of a human cadaver reveals drug-resistant strains and new fungal records.Applied microbiology and biotechnology · 2025Article
- Bacillus velezensis Bac-9, isolated from kefir, possesses antifungal activity and improves resistance of tomato plant against whitefly Bemisia tabaci.BMC microbiology · 2025Article
- Exploring fungal survival mechanisms: toward next-generation antifungal therapies against Candida spp.Archives of microbiology · 2025Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- Structural Insights into Selectively TargetingBiochemistry · 2025Article
- Antifungal Structure-Activity Relationship Studies of Broad-Spectrum Phenothiazines.ACS omega · 2025Article
- A novel pan-fungal screening platform for antifungal drug discovery: proof of principle study.Antimicrobial agents and chemotherapy · 2025Article
- Development of Efficient Covalent Inactivators of a Fungal Aspartate Semialdehyde Dehydrogenase.Drug development research · 2025Article
- Coccidioidomycosis: a growing global concern.The Journal of antimicrobial chemotherapy · 2025Review
- A comprehensive insight into naphthalimides as novel structural skeleton of multitargeting promising antibiotics.Future medicinal chemistry · 2025Review
- Special Issue "Antifungal Drug Discovery: Progresses, Challenges, Opportunities".International journal of molecular sciences · 2025Article
- Antifungal Natural Products Originating from Endophytic and Rhizospheric Microbes Isolated from Coastal Vegetation.Journal of xenobiotics · 2025Review
- Feature Reviews in Medicinal Chemistry.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The Role of Oxidative Stress in the Antifungal Activity of Two Mollusk Fractions on Resistant Fungal Strains.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The utility of clinically available antifungals is limited by their narrow spectrum of activity, high toxicity, and emerging resistance. Antifungal drug discovery has always been a challenging area, since fungi and their human host are eukaryotes, making it difficult to identify unique targets for antifungals. Novel antifungals in clinical development include first-in-class agents, new structures for an established target, and formulation modifications to marketed antifungals, in addition to repurposed agents. Membrane interacting peptides and aromatherapy are gaining increased attention in the field. Immunotherapy is another promising treatment option, with antifungal antibodies advancing into clinical trials. Novel targets for antifungal therapy are also being discovered, allowing the design of new promising agents that may overcome the resistance issue. In this mini review, we will summarize the current status of antifungal drug pipelines in clinical stages, and the most recent advancements in preclinical antifungal drug development, with special focus on their chemistry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.